Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Two recent Cochrane reviews report effective regimens
| The first 150 words of the full text of this article appear below. |
Exacerbations of chronic obstructive pulmonary disease affect quality of life and the cost of managing the disease. Though the long term effects of hypersecretion on the deterioration of ventilatory function in patients with chronic obstructive pulmonary disease have been debated for many years,1 recent data show a good correlation between hypersecretion and long term deterioration of ventilatory function in these patients.2 This is why mucolytics, which seem to have an effect on hypersecretory exacerbations,3 might also influence disease progression in chronic obstructive pulmonary disease. Exacerbations are important events for patients with chronic bronchitis in that they negatively affect quality of life.1 Exacerbations also have socio-economic consequences.2 Therapies aiming at reducing the occurrence and severity of exacerbations are therefore of interest.
The Cochrane review in this week's issue of the BMJ
reports a meta-analysis of drugs considered to have mucolytic effects (p 1271).3 Twenty two studies of 10 drugs were included.
Read all Rapid Responses
What can you learn from this BMJ paper? Read Leanne Tite's Paper+